SpongeBob126/OpenSECFinancials huggingface dataset:
iCoreConnect Inc (ICCT, Nasdaq)
Headquarters: Ocoee, FL, US
Sector: healthcare
Industry: health-information-services
Employees: 17
IPO date: 2022-04-19

iCoreConnect Inc. develops and markets health insurance portability and accountability act (HIPAA) compliant cloud-based software as a service (SaaS) in the United States. The company offers iCoreRx, a HIPAA compliant electronic prescription software; iCorePDMP, an add-on for iCoreRx that integrates with state databases to automate prescription drug monitoring; iCoreVerify and iCoreVerify+, a HIPAA compliant SaaS solution that automatically retrieves a patient insurance eligibility breakdown to verify their benefits; iCoreClaims for processing and managing claims submitted by policyholders or dental care provider; and iCoreHuddle and iCoreHuddle+, which reveals the revenue potential of each patient. It also provides iCoreCodeGenius, a medical coding reference SaaS solution; iCoreExchange, a HIPAA compliant SaaS email solution using direct protocol that allows doctors to send and receive secure email with attachments to and from other healthcare professionals in the network; iCoreCloud provides the ability to backup on-premise servers and computers to the cloud; iCorePay, a cloud-based financial technology solution designed to streamline the billing and payment processes for healthcare providers; iCoreSecure, a secure SaaS solution that solves privacy concerns; and iCoreIT. In addition, the company offers iCoreVerify provides automated insurance verifications; iCoreVerify+ that combines automation with concierge assistance for verification; and iCoreVerifyPro, it manages all verifications, entering insurance benefits directly into patient charts, ensuring insurance information. The company was formerly known as iMedicor, Inc. and changed its name to iCoreConnect Inc. in June 2017. The company was founded in 1992 and is headquartered in Ocoee, Florida. On June 2, 2025, iCoreConnect Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Middle District of Florida.
Elanco Animal Health Inc (ELAN, New York Stock Exchange)
Headquarters: Indianapolis, IN, US
Sector: healthcare
Industry: drug-manufacturers-specialty-generic
Employees: 9400
IPO date: 2018-09-20

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. It also provides farm animal products that help farmers improve animal health and wellbeing, and raise livestock, such as cattle, swine, and poultry. In addition, the company offers medicated feed additives, injectable antibiotics, vaccines, insecticides and enzymes, and others under the Rumensin, Baytril, and Experior trademarks for cattle; and under the Maxiban and Monteban trademarks for the control and prevention of intestinal disease in poultry. Further, it offers other pet health products for cats and dogs under the Atopica, Milbemax, Onsior, and Tru Family trademarks; and other farm animal products for poultry, cattle, and swine under the AviPro, Catosal, Denagard, Hemicell, Pulmotil, and Surmax tradmarks. The company sells its products to third-party distributors and independent retailers; and directly to farm animal producers and veterinarians. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Indianapolis, Indiana.
Novabridge Biosciences (IMAB, Nasdaq)
Headquarters: Rockville, MD, US
Sector: healthcare
Industry: biotechnology
Employees: 30
IPO date: 2020-01-17

NovaBridge Biosciences, a biotechnology company, engages in the research and development of immuno-oncology agents for the treatment of cancer in the United States. The company operates through two segments, Oncology and Ophthalmology. Its product pipeline comprises givastomig, a potential CLDN18.2 bispecific antibody, which is in phase 2 clinical trial combination with nivolumab and chemotherapy for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies; Phase 1b clinical trial in combination with nivolumab and chemotherapy in first-line gastric cancer. The company also develops VIS-101, VEGF-A × ANG-2 bispecific biologics in Phase 2 clinical trial to treat wet age-related macular degeneration and other retinal diseases, including diabetic macular edema; ragistomag, which is in Phase 1clinical trial for multiple solid tumors. It has a licensing agreement with AskGene to develop and commercialize VIS-101; collaborations with Bristol Myers Squibb for the development of givastomig; and license and collaboration agreement with AbbVie Ireland Unlimited Company for the development and commercialization of lemzoparlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
Merchants Bancorp (MBIN, Nasdaq)
Headquarters: Carmel, IN, US
Sector: financial-services
Industry: banks-regional
Employees: 735
IPO date: 2017-10-27

Merchants Bancorp operates as the diversified bank holding company in the United States. It operates through three segments: Multi-family Mortgage Banking, Mortgage Warehousing, and Banking. The Multi-family Mortgage Banking segment engages in the mortgage banking, which originates, and services government sponsored mortgages, including bridge financing products to refinance, acquire, or reposition multi-family housing projects, and construction lending for housing development and healthcare facilities financing. This segment also offers customized loan products for need-based skilled nursing facilities, such as independent living, assisted living, and memory care; and tax credit equity syndicator service. The Mortgage Warehousing segment funds agency eligible residential loans, as well as commercial loans to non-depository financial institutions. The Banking segment offers a range of financial products and services to consumers and businesses, which includes retail banking, commercial lending, agricultural lending, retail and correspondent residential mortgage banking, and small business administration lending. Merchants Bancorp was founded in 1990 and is headquartered in Carmel, Indiana.
Employers Holdings Inc (EIG, New York Stock Exchange)
Headquarters: Reno, NV, US
Sector: financial-services
Industry: insurance-specialty
Employees: 623
IPO date: 2007-01-31

Employers Holdings, Inc., through its subsidiaries, provides workers' compensation insurance and services in the United States. The company offers insurance to small businesses in low to medium hazard industries. It market its products through local, regional, specialty and national insurance agents and brokers; national, regional, and local trade groups and associations; and direct-to-customer interactions. Employers Holdings, Inc. was founded in 2000 and is based in Reno, Nevada.
Embrace Change Acquisition Corp. (EMCGR, Nasdaq)
Headquarters: San Diego, CA, US
Sector: financial-services
Industry: shell-companies
IPO date: 2022-09-30

Embrace Change Acquisition Corp. does not have significant operations. It intends to enter into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2021 and is based in San Diego, California.
Eltek Ltd (ELTK, Nasdaq)
Headquarters: Petah Tikva, , US
Sector: technology
Industry: electronic-components
Employees: 352
IPO date: 1997-01-23

Eltek Ltd. engages in the manufacture, marketing, and sale of printed circuit boards (PCBs) in Israel, North America, India, the Netherlands, rest of Europe, and internationally. The company offers various custom designed PCBs, including complex rigid, double-sided and multi-layer PCBs, and flexible circuitry boards. It also provides high-density circuit boards; and flexible and flex rigid PCBs, and multi-layered boards, as well as act as a supplier for the importation of PCBs. In addition, the company provides training and consulting services. It primarily serves medical technology, defense and aerospace, industrial, telecom, and networking equipment industries, as well as contract electronic manufacturers. The company markets and sells its products primarily through direct sales personnel, sales representatives, and PCB trading and manufacturing companies. Eltek Ltd. was incorporated in 1970 and is headquartered in Petah Tikva, Israel. Eltek Ltd. operates as a subsidiary of Nistec Golan Ltd.
Intelligent Living Application Group Inc (ILAG, Nasdaq)
Headquarters: Kwai Chung, , US
Sector: industrials
Industry: building-products-equipment
Employees: 198
IPO date: 2022-07-13

Intelligent Living Application Group Inc., through its subsidiaries, manufactures and sells mechanical locksets to customers mainly in the United States and Canada. It offers locksets functions, deadbolts, entry locksets, privacy locksets, passage locksets, and storeroom locks under the Bamberg and Kambo brand names. The company offers locksets for outdoor uses, such as main entrances and gates, and indoor uses. Intelligent Living Application Group Inc. was founded in 1981 and is headquartered in Kwai Chung, Hong Kong.
Icon Plc (ICLR, Nasdaq)
Headquarters: Dublin, , US
Sector: healthcare
Industry: diagnostics-research
Employees: 39800
IPO date: 1998-05-15

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Intapp Inc (INTA, Nasdaq)
Headquarters: Palo Alto, CA, US
Sector: technology
Industry: software-application
Employees: 1336
IPO date: 2021-06-30

Intapp, Inc., through its subsidiary, Integration Appliance, Inc., provides AI-powered solutions in the United States, the United Kingdom, and internationally. It provides DealCloud that manages client relationships, prospective clients, investments, and current engagements, as well as provides customer relationship management, deal management, experience management, and relationship intelligence solutions. The company also offers compliance products that help firms thoroughly evaluate new business, onboard clients quickly, and monitor relationships for risk throughout their business lifecycle; and time solutions provides AI-enabled software solutions that include time capture, enhance billing, and facilitate compliance with client requirements. In addition, it provides collaboration products that offer intelligent client-centric teamwork with Microsoft 365, Teams, and SharePoint; a unified system for managing emails, documents, chats, and tasks; and Assist, an AI-driven transformation that integrates advanced machine learning and natural language processing into Intapp products, such as Intapp DealCloud and Intapp Terms, as well as streamlines critical workflows, enhances decision-making, and delivers measurable results. Further, the company operates technology platforms, such as cloud-based architecture, low-code configurability and personalized UX, applied AI, and industry-specific data architecture. It serves private capital, investment banking, legal, accounting, and consulting firms, and real assets. The company was formerly known as LegalApp Holdings, Inc. and changed its name to Intapp, Inc. in February 2021. Intapp, Inc. was founded in 2000 and is headquartered in Palo Alto, California.
Imunon Inc (IMNN, Nasdaq)
Headquarters: Lawrenceville, NJ, US
Sector: healthcare
Industry: biotechnology
IPO date: 1999-03-01

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines in the United States. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy that is in a Phase 3 clinical trial for the localized treatment of advanced ovarian cancer, as well as in the IND-enabling phase for colorectal and pancreatic cancers, and in the discovery phase for glioblastoma. It is also developing IMNN-101, a COVID-19 booster vaccine that has completed a Phase 1 clinical trial. In addition, the company develops non-viral DNA technology across modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response. The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. Imunon, Inc. was incorporated in 1982 and is headquartered in Lawrenceville, New Jersey.
Ingredion Inc (INGR, New York Stock Exchange)
Headquarters: Westchester, IL, US
Sector: consumer-defensive
Industry: packaged-foods
Employees: 11000
IPO date: 1997-12-11

Ingredion Incorporated, together with its subsidiaries, engages in the manufacture and sale of sweeteners, starches, nutrition ingredients, and biomaterial solutions derived from wet milling and processing corn, and other starch-based materials to a range of industries worldwide. The company operates in Texture & Healthful Solutions; Food & Industrial IngredientsLATAM; and Food & Industrial IngredientsU.S./CANADA segments. It offers starch products for use in a range of processed foods; cornstarch; specialty paper starches for enhanced drainage, fiber retention, oil and grease resistance, improved printability, and biochemical oxygen demand control; starches and specialty starches for textile industry; industrial starches are used in the production of construction materials, textiles, adhesives, pharmaceuticals, and cosmetics, as well as in mining and water filtration; and specialty industrial starches for use in biomaterial applications, including biodegradable plastics, fabric softeners and detergents, hair and skin care applications, dusting powders for surgical gloves, and in the production of glass fiber and insulation. The company provides sweetener products comprising glucose syrups, high maltose syrup, high fructose corn syrup, dextrose, polyols, maltodextrin, glucose syrup solids, and non-genetically modified organism syrups for applications in food and beverage products, such as baked goods, snack foods, canned fruits, condiments, candy and other sweets, dairy products, ice cream, jams and jellies, prepared mixes, table syrups, and beverages. In addition, the company sells refined corn oil, corn gluten feed, and corn gluten meal; and other products. The company was formerly known as Corn Products International, Inc. and changed its name to Ingredion Incorporated in June 2012. Ingredion Incorporated was founded in 1906 and is headquartered in Westchester, Illinois.
Intelligent Bio Solutions Inc (INBS, Nasdaq)
Headquarters: New York, NY, US
Sector: healthcare
Industry: medical-devices
Employees: 53
IPO date: 2020-12-23

Intelligent Bio Solutions Inc., a medical technology company, focused on developing and delivering non-invasive testing, and screening solutions in Asia Pacific, the United States, the United Kingdom, and internationally. The company operates intelligent fingerprinting drug screening system, a platform to analyze fingerprint sweat analysis to detect drugs abuse; and biosensor platform. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. Intelligent Bio Solutions Inc. was incorporated in 2016 and is headquartered in New York, New York.
Infosys Ltd (INFY, New York Stock Exchange)
Headquarters: Bengaluru, , US
Sector: technology
Industry: information-technology-services
Employees: 328594
IPO date: 1999-03-11

Infosys Limited provides consulting, technology, outsourcing, and digital services worldwide. It provides digital marketing and digital workplace, digital commerce, digital experience and interactions, and metaverse; data analytics and AI, applied AI, generative AI, and sustainability; blockchain, engineering, and Internet of Things; enterprise agile DevOps, API economy and microservices, application modernization, cloud, digital process automation, digital supply chain, Microsoft business application and cloud business, service experience transformation, energy transition, Network Transformation Services, Infrastructure Services cyber security, and quality engineering solutions; Oracle, SAP, and Saleforce solutions; Topaz, an AI-first set of services, solutions, and platforms using generative AI technologies; and Aster, a set of AI-amplified marketing services, solutions, and platforms. The company also offers Finacle, a core banking solution; Edge suite of products; Panaya platform, Infosys Equinox, Infosys Live Enterprise Suite, Infosys Wingspan, Infosys Helix, Infosys Meridian, Infosys Polycloud, Infosys Cortex, and Stater digital platforms; and Infosys McCamish, an insurance platform. It serves aerospace and defense, agriculture, automotive, chemical manufacturing, communication, consumer packaged goods, education, engineering procurement and construction, financial, healthcare, high technology, industrial manufacturing, information services and publishing, insurance, life science, logistics and distribution, media, entertainment, mining, oil and gas, private equity, professional, public, retail, semiconductor, travel, hospitality, utilities, and waste management industries. It has a strategic collaboration with Anthropic PBC, Intel, and Harness Inc. The company was formerly known as Infosys Technologies Limited and changed its name to Infosys Limited in June 2011. Infosys Limited was incorporated in 1981 and is headquartered in Bengaluru, India.
Intel Corp (INTC, Nasdaq)
Headquarters: Santa Clara, CA, US
Sector: technology
Industry: semiconductors
Employees: 85100
IPO date: 1980-03-17

Intel Corporation designs, develops, manufactures, markets, sells, and services computing and related end products and services in the United States, Ireland, Israel, and internationally. It operates through three segments: CCG, DCAI, and Intel Foundry. The company offers client computing group products, including client and commercial CPUs, discrete client GPUs, edge computing, and connectivity products; data center and AI products, such as server CPUs, discrete GPUs, and networking products; and semiconductors comprising wafer fabrication, substrates, and other related products and services. It also provides driving assistance and self-driving solutions; and develops and manufactures multi-beam mask writing tools. The company sells its products through sales organizations, distributors, resellers, retailers, and OEM partners. It serves original equipment manufacturers, original design manufacturers, cloud service providers, and other manufacturers and service providers. Intel Corporation has a strategic collaboration with Infosys Limited to develop a multi-layer AI fabric that unifies infrastructure, models, data, applications, and workflows into a composable and agent-ready ecosystem. The company was incorporated in 1968 and is headquartered in Santa Clara, California.
Immersion Corp (IMMR, Nasdaq)
Headquarters: Aventura, FL, US
Sector: technology
Industry: software-application
Employees: 2360
IPO date: 1999-11-12

Immersion Corporation, together with its subsidiaries, engages in the business of intellectual property (IP) that engages users' sense of touch when operating digital devices in North America, Europe, and Asia. The company offers software, related tools and technical assistance related to integrating its patented technology; educational content and general merchandise, and digital and physical textbooks through its bookstore locations, including virtual bookstores, and bookstore-affiliated e-commerce websites; and marketing services, including promotional activities and advertisements, as well as operates as a textbook wholesaler, and bookstore management hardware and software provider. It serves various markets, such as mobile devices, wearables, consumer, mobile entertainment, and other content; console gaming; automotive; medical; and commercial. The company was incorporated in 1993 and is headquartered in Aventura, Florida.
IN8bio Inc (INAB, Nasdaq)
Headquarters: New York, NY, US
Sector: healthcare
Industry: biotechnology
Employees: 17
IPO date: 2021-07-30

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer; and INB-600, a gamma-Delta T cell engager. In addition, it is developing INB-619, a gamma-delta TCE targeting CD19 for potential applications in both oncology and autoimmune diseases. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.
Inhibrx Inc (INBX, Nasdaq)
Headquarters: La Jolla, CA, US
Sector: healthcare
Industry: biotechnology
Employees: 109
IPO date: 2020-08-19

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.
Innodata Inc (INOD, Nasdaq)
Headquarters: Ridgefield Park, NJ, US
Sector: technology
Industry: information-technology-services
Employees: 10020
IPO date: 1993-08-11

Innodata Inc. operates as a data engineering company in the United States, the United Kingdom, the Netherlands, Canada, Germany, Belgium, and internationally. The company operates through three segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment engages in the provision of artificial intelligence (AI) training and post-training data, model evaluation, alignment, safety, AI model deployment and integration, and AI-enabled platforms. The Synodex segment offers an industry platform that transforms medical records into structured digital data for insurance and healthcare workflows. The company also provides Agility PR Solutions platform that provides media intelligence and public relations workflow software enhanced with AI-driven monitoring, analytics, and content capabilities. It serves banking, insurance, financial services, technology, digital retailing, and information media sectors through its professional staff, senior management, and direct sales personnel. The company was formerly known as Innodata Isogen Inc. and changed its name to Innodata Inc. in November 2003. Innodata Inc. was incorporated in 1988 and is headquartered in Ridgefield Park, New Jersey.
InMed Pharmaceuticals Inc (INM, Nasdaq)
Headquarters: Vancouver, BC, US
Sector: healthcare
Industry: drug-manufacturers-specialty-generic
Employees: 13
IPO date: 2007-07-24

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Intellinetics Inc (INLX, NYSE MKT)
Headquarters: Columbus, OH, US
Sector: technology
Industry: software-application
Employees: 148
IPO date: 2015-03-10

Intellinetics, Inc. designs, develops, tests, markets, and licenses document services and software solutions in the United States. The company operates through two segments, Software and Document Conversion. The company's software platform allows its customers to capture and manage documents across operations, such as scanned hard-copy documents and digital documents, including Microsoft Office 365, digital images, audio, videos, and emails. Its flagship software suite includes IntelliCloud platform that comprises image processing modules, accounts payable lifecycle automation, records management, workflow, and extended components; and YellowFolder, a specialized content management software solution for the K-12 education market. The company also provides installation, integration, training, and consulting services; ongoing software maintenance and customer support services; and digital scanning, microfilm and microfiche conversion, box storage, and repair and maintenance services, as well as long-term paper and microfilm storage, and retrieval option services. In addition, it offers business process outsourcing services. The company sells its products to resellers and directly to customers; and provides access to its software solutions as a service through the Internet. The company serves businesses; state, county, and municipal governments; and healthcare, K-12 education, public safety, other public sector, risk management, financial services, and others. The company was formerly known as GlobalWise Investments, Inc. and changed its name to Intellinetics, Inc. in September 2014. Intellinetics, Inc. was founded in 1996 and is headquartered in Columbus, Ohio.
Indonesia Energy Corp Ltd (INDO, NYSE MKT)
Headquarters: Jakarta, , US
Sector: energy
Industry: oil-gas-e-p
IPO date: 2019-12-20

Indonesia Energy Corporation Limited, together with its subsidiaries, operates as an oil and gas exploration and production company in Indonesia. Its principal assets include the Kruh Block, a producing block covering an area of 258 square kilometers located in the Pali, South Sumatra; and the Citarum Block, an exploration block covering approximately an area of 3,924.67 square kilometers located in the onshore of West Java. The company was incorporated in 2018 and is headquartered in Jakarta, Indonesia.
Rowan Companies Plc (RDC, New York Stock Exchange)
Headquarters: , , US
IPO date: 1983-04-06
Delisted: 2019-04-11

Valaris Limited (previously ENSCO-Rowan plc) is an offshore drilling contractor headquartered in Houston, Texas, and incorporated in Bermuda. It is the largest offshore drilling and well drilling company in the world, and owns 52 rigs, including 36 offshore jackup rigs, 11 drillships, and 5 semi-submersible platform drilling rigs.
In 2022, the company's largest customer was BP (15% of revenues).
Regions Financial Corp (RF-P-A, New York Stock Exchange)
Headquarters: , , US
IPO date: 2014-09-22
Delisted: 2021-06-14

Regions Financial Corporation is an American bank holding company headquartered in the Regions Center in Birmingham, Alabama. The company provides retail and commercial banking, trust, stock brokerage, and mortgage services. Its banking subsidiary, Regions Bank, operates about 2,000 automated teller machines and 1,300 branches in 15 states in the Southern and Midwestern United States. Regions is ranked 483rd on the Fortune 500 and 140th on Fortune's list of "America's Most Innovative Companies. Component headquartered in Alabama, Regions is also on the list of largest banks in the United States.
Regions is ranked 434th on the Fortune 500 and is component headquartered in Alabama. Regions is also on the list of largest banks in the United States.
Regions is the largest deposit holder in Alabama and Tennessee. It is also one of the largest deposit holders in Arkansas, Louisiana, Mississippi, and Florida.
The company sponsors Regions Field, a Minor League Baseball stadium in Birmingham, Alabama, and the Tradition golf tournament. It sponsored the Regions Charity Classic, a golf tournament held in 2009 and 2010.
The company has a partnership with Operation HOPE, Inc. to provide free financial education to underserved communities. In 2019, the company expanded its Workday, Inc. system in partnership with EnterpriseAlumni to engage and enable ex-employees to extend their corporate social responsibility initiatives.
Integral Acquisition Corp 1 (INTEU, Nasdaq)
Headquarters: New York, NY, US
Sector: financial-services
Industry: shell-companies
IPO date: 2021-11-03

Integral Acquisition Corporation 1 does not have significant operations. The company intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It focuses on acquiring technology-oriented companies in Australia and New Zealand. The company was incorporated in 2021 and is based in New York, New York. Integral Acquisition Corporation 1 is a subsidiary of Integral Sponsor LLC.
Immunovant Inc (IMVT, Nasdaq)
Headquarters: Durham, NC, US
Sector: healthcare
Industry: biotechnology
Employees: 362
IPO date: 2019-12-19

Immunovant, Inc., a clinical-stage immunology company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1402 for graves' disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, cutaneous lupus erythematosus disease, and sjögren's disease; and batoclimab for myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and thyroid eye disease. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Immatics N.V (IMTX, Nasdaq)
Headquarters: Tübingen, , US
Sector: healthcare
Industry: biotechnology
Employees: 589
IPO date: 2020-07-02

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
Rhodia (RHAYY, New York Stock Exchange)
Headquarters: , , US
IPO date: 2007-09-28
Delisted: 2012-10-01

The word Rhodia may refer to:

In Greek mythology (Ῥόδεια, Ῥοδία):
Rhodea, Rhodeia, or Rhodia, one of the Oceanids
Rhodia, one of the Danaïdes
Rhodia, one of the Muses
Rhodia, a fictional planet of the Nebula Kingdoms in Asimov's Empire Series
437 Rhodia, an asteroid
Rhodia (company), a French chemical company
Clairefontaine-Rhodia branch of Clairefontaine paper mills who acquired French paper company Rhodia in 1997
Rhodia, a city, also called Rhodiopolis, of ancient Lycia
Inuvo Inc (INUV, NYSE MKT)
Headquarters: Little Rock, AR, US
Sector: technology
Industry: software-application
Employees: 72
IPO date: 1998-08-04

Inuvo, Inc., an advertising technology and services company, develops and commercializes large language generative artificial intelligence that discovers and targets digital audiences in the United States. The company offers IntentKey, an artificial intelligence, data analytics, and automation tool that can optimize the purchase and placement of advertising in real time without consumer data, which can serve multiple creative formats including agencies and brands; CTV, video, audio, native, display channels; and platform. The company sells its information technology solutions to agencies, brands, and large consolidators of advertising demand. It markets its products through websites, social media platforms, blogs, public relations, trade shows, and conferences. The company is headquartered in Little Rock, Arkansas.
Invo Fertility Inc. (INVO, Nasdaq)
Headquarters: Sarasota, FL, US
Sector: healthcare
Industry: medical-devices
Employees: 33
IPO date: 2012-05-21

INVO Fertility, Inc., a healthcare services company, focuses on the fertility marketplace that provides assisted reproductive technology care to patients. It operates through Fertility Clinic Services; INVOcell Device; and Therapeutics segments. The company offers INVOcell Device, a medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. It also operates fertility clinics, including INVO Centers. In addition, the company develops NY-303, a GPC3 x NKp46 bifunctional antibody that is in Phase i/ii a monotherapy trial for the treatment of hepatocellular carcinoma; and NY-500, an AI-optimized bifunctional antibody. The company was formerly known as NAYA Biosciences, Inc. and changed its name to INVO Fertility, Inc. in April 2025. INVO Fertility, Inc. was founded in 2007 and is based in Sarasota, Florida.
Mesa Air Group Inc (RJET, Nasdaq)
Headquarters: Phoenix, AZ, US
Sector: industrials
Industry: airlines
Employees: 2303
IPO date: 2004-05-27
Delisted: 2016-03-07

Mesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc. that provides regional air carrier scheduled passenger services. The company offers scheduled flight and cargo services. As of September 30, 2023, it operated a fleet of 80 aircraft with approximately 296 daily departures to 86 cities in the United States and Mexico. Mesa Air Group, Inc. was founded in 1982 and is headquartered in Phoenix, Arizona.
Assure Holdings Corp (IONM, Nasdaq)
Headquarters: Denver, CO, US
Sector: healthcare
Industry: medical-care-facilities
Employees: 95
IPO date: 2017-07-19

Assure Holdings Corp., through its subsidiaries, provides technical and professional intraoperative neuromonitoring surgical support services in the United States. The company offers services in the areas of neurosurgery, spine, cardiovascular, orthopedic, ear, nose, throat, and other surgical procedures that place the nervous system at risk. It delivers various clinical and operational services, including scheduling of the interoperative neurophysiologist and supervising practitioner, real time monitoring, patient advocacy, and billing and collection services to support surgeons and medical facilities during invasive procedures. The company is based in Denver, Colorado.
Intuitive Surgical Inc (ISRG, Nasdaq)
Headquarters: Sunnyvale, CA, US
Sector: healthcare
Industry: medical-instruments-supplies
Employees: 17021
IPO date: 2000-06-16

Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
IF Bancorp Inc (IROQ, Nasdaq)
Headquarters: Watseka, IL, US
Sector: financial-services
Industry: banks-regional
Employees: 104
IPO date: 2011-07-08

IF Bancorp, Inc. operates as the savings and loan holding company for Iroquois Federal Savings and Loan Association that provides a range of banking and financial services to individual and corporate clients. The company offers various deposit accounts, including savings accounts, certificates of deposit, money market accounts, commercial and personal checking accounts, individual retirement accounts, and health savings accounts. It provides loans comprising one- to four-family residential mortgage loans; multi-family mortgage loans; commercial real estate loans, such as farm loans; home equity lines of credit; commercial business loans; and consumer loans primarily comprising automobile loans, as well as construction loans and land development loans. In addition, the company sells property and casualty insurance, as well as offers annuities; mutual funds; individual and group retirement plans; life, disability, and health insurance; individual securities; managed accounts; and other financial services. Further, it invests in securities; and provides ATM, online banking and bill pay, mobile banking, ACH origination, remote deposit capture, and telephone banking services. IF Bancorp, Inc. was founded in 1883 and is headquartered in Watseka, Illinois.
Iovance Biotherapeutics Inc (IOVA, Nasdaq)
Headquarters: San Carlos, CA, US
Sector: healthcare
Industry: biotechnology
Employees: 975
IPO date: 2010-10-15

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.
IQVIA Holdings Inc (IQV, New York Stock Exchange)
Headquarters: Durham, NC, US
Sector: healthcare
Industry: diagnostics-research
Employees: 93000
IPO date: 2013-05-09

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
Identiv Inc (INVE, Nasdaq)
Headquarters: Santa Ana, CA, US
Sector: industrials
Industry: building-products-equipment
Employees: 155
IPO date: 1997-10-07

Identiv, Inc., develops, manufactures, and supplies specialty IoT products in the United States, Europe, the Middle East, and the Asia-Pacific. The company offers specialty radio-frequency identification (RFID) and Internet of Things (IoT) devices, including near field communication, high frequency, dual frequency, ultra-high frequency, and bluetooth low energy that are attached to or embedded into physical items, such as medical device consumables, pill containers, wine bottles, consumer appliances, and sports jerseys, providing unique digital identity. It serves its products to pharmaceutical and medical devices, consumer electronics, mobile devices, wine and spirits, luxury goods, libraries, and logistics. The company was formerly known as Identive Group, Inc. and changed its name to Identiv, Inc. in May 2014. Identiv, Inc. was founded in 1990 and is headquartered in Santa Ana, California.
Innate Pharma Sa (IPHA, Nasdaq)
Headquarters: Marseille, , US
Sector: healthcare
Industry: biotechnology
Employees: 164
IPO date: 2019-10-17

Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France.